A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.